SFM
GPCR icon

Sphera Funds Management’s Structure Therapeutics GPCR Stock Holding History

Sphera Funds Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Sell
28,600
-22,200
-44% -$982K 0.2% 92
2026
Q1 		$2.45M Buy
50,800
+9,800
+24% +$671K 0.39% 73
2025
Q4 		$2.85M Sell
41,000
-132,931
-76% -$5.43M 0.55% 65
2025
Q3 		$4.87M Buy
173,931
+78,000
+81% +$1.55M 1.03% 33
2025
Q2 		$1.99M Buy
95,931
+11,931
+14% +$262K 0.47% 69
2025
Q1 		$1.45M Buy
+84,000
New +$2.06M 0.33% 77

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Sphera Funds Management's GPCR Position: Q2 2026 in Review

Sphera Funds Management reduced its Structure Therapeutics (GPCR) stake by 44% in Q2 2026, selling an estimated $982K and leaving 28,600 shares worth $1.53M. The position accounts for 0.2% of the portfolio, ranked #92.

Sphera Funds Management first reported a position in GPCR in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.87M in Q3 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Sphera Funds Management held 28,600 shares of Structure Therapeutics worth $1.53M as of Q2 2026.
  • Sphera Funds Management sold 22,200 Structure Therapeutics shares in Q2 2026, an estimated $982K.
  • Structure Therapeutics made up 0.2% of Sphera Funds Management's portfolio in Q2 2026, its #92 holding.
  • Sphera Funds Management first reported a position in Structure Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Sphera Funds Management's Structure Therapeutics position peaked at $4.87M in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.